We are seeing significant physician interest in utilizing Apifiny to improve the assessment of prostate cancer risk.
Ann Arbor, Michigan (PRWEB) May 19, 2015
Armune BioScience today announced that it has been selected to present at the 2015 Michigan Growth Capital Symposium. The company, focused on commercializing the only cancer specific, non-PSA blood test to aid in the detection of prostate cancer, is among a roster of promising, high-growth companies from the Midwest and beyond seeking funding in the next 12 months. Armune BioScience will deliver its 10-minute presentation to attending investors, which include nearly 100 regional and top national venture capital firms, on Wednesday, May 20 at 10:20 AM.
The Michigan Growth Capital Symposium, known for attracting high-quality investors from around the country, is the oldest university-based venture capital fair and the premier Midwest networking event for leaders in venture capital investment. Now in its 34th year, the Symposium serves as a conduit for introducing early stage and emerging growth companies seeking funding to U.S. investors prospecting deals.
Armune, beginning in April, has begun to drive solid volume growth of its flagship product, Apifiny, the only cancer specific, non-PSA blood test available to aid in the detection of prostate cancer. The company is raising $2.5 million as part of a Series A round of financing. David Esposito, President and CEO, will be presenting for the company.
“This is an exciting time for Armune to be presenting this year at the Michigan Growth Capital Symposium,” commented David Esposito. “We have just recently opened our lab and are exceeding our growth expectations for Apifiny. We are seeing significant physician interest in utilizing Apifiny to improve the assessment of prostate cancer risk. We look forward to funding our expansion plans in order to realize the full potential of our product line.”
More than 450 entrepreneurs, researchers, investment professionals and business executives are expected to attend the Symposium, taking place May 19-20 at the Marriott Resort in Ypsilanti, Mich. In addition to company presentations, the two-day event will feature keynote addresses from Bill Coughlin, president and CEO of Ford Global Technologies and Brad Keywell, the co-founder of Groupon and current CEO and co-founder of Uptake.
“The influx of innovation, venture capital and entreprenuerial activity continues to boom in the Midwest,” said David J. Brophy, Michigan Growth Capital Symposium founder and director and professor of finance at the University of Michigan Ross School of Business. “Armune BioScience is an example of a high caliber organization homegrown in Michigan and a testament to why investors across the country are paying closer attention to the region.”
To learn more, see the full list of presenting companies or register, visit http://www.MichiganGCS.com and follow conversations about the Symposium by tracking #MGCS2015 on Twitter. For more information about Armune BioScience, please visit: http://www.armune.com
About Armune BioScience
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The company was founded by members of the Apjohn Group, LLC (http://www.apjohngroup.com ), a business accelerator founded by experienced health care executives that brings together valuable resources of management talent, angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.
About the Michigan Growth Capital Symposium (MGCS)
MGCS is presented by the Ross School of Business at the University of Michigan with support from the Michigan Venture Capital Association and the Michigan Economic Development Corporation. The Symposium offers the opportunity to build relationships with an unparalleled business network of distinguished private equity industry leaders, leading university research faculty and entrepreneurial business professionals.